These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 2577115

  • 1. Increased activated T-lymphocytes and normal thyrotropin receptor antibody levels in Graves' disease in long-term remission.
    Peakman M, Hussain M, Cundy T, Vergani D.
    J Clin Lab Immunol; 1989 Sep; 30(1):1-5. PubMed ID: 2577115
    [Abstract] [Full Text] [Related]

  • 2. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J.
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [Abstract] [Full Text] [Related]

  • 3. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease.
    Tötterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I.
    N Engl J Med; 1987 Jan 01; 316(1):15-22. PubMed ID: 2946953
    [Abstract] [Full Text] [Related]

  • 4. Absence of gradient of thyrotropin receptor antibody and T cell subset distribution between thyroid and peripheral venous blood in patients with Graves' disease prepared for surgery with carbimazole and potassium iodide.
    Wilson R, McKillop JH, Pearson C, Burnett AK, Gunn I, McNicol AM, Thomson JA.
    Clin Exp Immunol; 1988 Aug 01; 73(2):265-8. PubMed ID: 3263232
    [Abstract] [Full Text] [Related]

  • 5. Humoral and cellular immunological factors as possible markers of clinical relapse in HLA-typed Graves' patients followed with time.
    Di Mario U, Vitillo M, Perfetti R, Mancuso M, Morellini M, Cappellacci S, Pozzilli P, Andreani D.
    Horm Metab Res; 1989 May 01; 21(5):267-71. PubMed ID: 2789166
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differential immunosuppressive action of carbimazole and propylthiouracil.
    Wilson R, McKillop JH, Pearson C, Burnett AK, Thomson JA.
    Clin Exp Immunol; 1988 Aug 01; 73(2):312-5. PubMed ID: 3263234
    [Abstract] [Full Text] [Related]

  • 8. T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status.
    Madec AM, Allannic H, Genetet N, Gueguen M, Genetet G, Fauchet R, Stefanutti A, Orgiazzi J.
    J Clin Endocrinol Metab; 1986 Jan 01; 62(1):117-21. PubMed ID: 3484386
    [Abstract] [Full Text] [Related]

  • 9. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May 01; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 10. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET, Steel NR, Taylor JJ, Stephenson AM, Stratton A, Holcombe M, Kendall-Taylor P.
    Q J Med; 1988 Feb 01; 66(250):175-89. PubMed ID: 2902655
    [Abstract] [Full Text] [Related]

  • 11. Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.
    Charreire J, Karsenty G, Bouchard P, Schaison G.
    Clin Exp Immunol; 1984 Sep 01; 57(3):633-8. PubMed ID: 6147216
    [Abstract] [Full Text] [Related]

  • 12. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M, Minich WB, Willenberg HS, Papewalis C, Seissler J, Feldkamp J, Bergmann A, Scherbaum WA, Morgenthaler NG.
    Horm Metab Res; 2005 Dec 01; 37(12):741-4. PubMed ID: 16372227
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA.
    Clin Endocrinol (Oxf); 2004 Jun 01; 60(6):671-5. PubMed ID: 15163328
    [Abstract] [Full Text] [Related]

  • 20. Studies of autoimmunity in Graves' disease before and after treatment with carbimazole.
    Zosin I, Arcan P, Lungu G, Cotoi A, Opreanu R.
    Endocrinologie; 1988 Jun 01; 26(1):49-53. PubMed ID: 3260398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.